AMF Tjanstepension AB Makes New $1.46 Million Investment in Moderna, Inc. (NASDAQ:MRNA)

AMF Tjanstepension AB purchased a new position in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 35,203 shares of the company's stock, valued at approximately $1,464,000.

A number of other hedge funds also recently bought and sold shares of the stock. Intrinsic Value Partners LLC increased its stake in shares of Moderna by 91.1% during the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company's stock worth $3,435,000 after buying an additional 24,505 shares during the period. Banco Santander S.A. acquired a new position in Moderna during the 3rd quarter worth approximately $3,550,000. John G Ullman & Associates Inc. increased its position in shares of Moderna by 341.3% in the 3rd quarter. John G Ullman & Associates Inc. now owns 49,650 shares of the company's stock valued at $3,318,000 after purchasing an additional 38,400 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. increased its position in shares of Moderna by 11.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,614,313 shares of the company's stock valued at $107,885,000 after purchasing an additional 167,596 shares during the last quarter. Finally, abrdn plc raised its holdings in shares of Moderna by 28.1% in the 4th quarter. abrdn plc now owns 315,912 shares of the company's stock valued at $12,842,000 after purchasing an additional 69,360 shares in the last quarter. Institutional investors and hedge funds own 75.33% of the company's stock.

Analyst Upgrades and Downgrades

MRNA has been the subject of a number of analyst reports. HSBC upgraded shares of Moderna from a "hold" rating to a "buy" rating and set a $58.00 target price for the company in a research note on Monday, November 18th. Barclays downgraded Moderna from an "overweight" rating to an "equal weight" rating and dropped their price objective for the company from $111.00 to $45.00 in a report on Tuesday, February 18th. Argus cut Moderna from a "buy" rating to a "hold" rating in a research note on Wednesday, December 18th. Royal Bank of Canada reaffirmed a "sector perform" rating and issued a $40.00 price target on shares of Moderna in a report on Tuesday, February 18th. Finally, Piper Sandler reissued an "overweight" rating and set a $69.00 price objective (down previously from $115.00) on shares of Moderna in a report on Monday, November 18th. Four research analysts have rated the stock with a sell rating, fifteen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and a consensus price target of $60.63.

Remove Ads

Moderna Price Performance

Shares of NASDAQ:MRNA traded up $1.25 during trading on Wednesday, reaching $35.01. The company had a trading volume of 6,588,960 shares, compared to its average volume of 12,555,106. Moderna, Inc. has a fifty-two week low of $29.25 and a fifty-two week high of $170.47. The stock's fifty day moving average price is $36.38 and its 200 day moving average price is $48.11. The firm has a market capitalization of $13.51 billion, a price-to-earnings ratio of -3.77 and a beta of 1.86.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.